Safety of statins - Focus on clinical pharmacokinetics and drug interactions
Safety of statins - Focus on clinical pharmacokinetics and drug interactions
复制标题
DOI：
10.1161/01.cir.0000131519.15067.1f
复制
发表时间：
2004-06-15
期刊：
影响因子：
37.8
通讯作者：
Corsini, A
中科院分区：
文献类型：
--
作者：
Bellosta, S;Paoletti, R;Corsini, A
他汀类药物单一治疗一般耐受性好，不良反应发生率低。与他汀类药物相关的最重要的不良反应是肌病和肝转氨酶的无症状升高，这两种情况都很少见。然而，由于他汀类药物的处方是长期的，可能与其他药物的相互作用值得特别关注，因为许多患者在他汀类药物治疗过程中通常会接受伴随条件的药物治疗。本文综述了他汀类药物的药代动力学特性，并强调了它们与临床相关的药物相互作用。
Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently. Because statins are prescribed on a long-term basis, however, possible interactions with other drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment. This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions.